Sama Pharm received approval for the first generic of the COPD treatment ‘Daxas (roflumilast, AstraZeneca Korea)'.

As Sama was the only company that succeeded in avoiding the composition patent of Daxas, if the generic is released immediately, the company will be able to preoccupy and monopolize the market for the time being.

The Ministry of Food and Drug Safety approved Sama Pharm’s ‘Samaloflu 500mg microgram tablets’ on the 13th. The drug is a generic drug of Daxas 500 micrograms tablets, and the first generic of its kind to be approved in Korea.

The drug may be used as add-on therapy to bronchodilator treatment or as maintenance treatment of severe chronic obstructi